| Document |
Document Title |
|
WO/2016/168704A1 |
This invention relates to antagonists of Kinase Suppressor of Ras (KSR). Pharmaceutical compositions comprising KSR inhibitors and methods of treating cancer are also provided.
|
|
WO/2015/112739A9 |
Disclosed are compounds and a method of treating cancer that is PARP1-deficient compared to a wild-type form of the same cancer, the method involving administering an effective amount of a compound selected from and, in which ring A1, ri...
|
|
WO/2016/165205A1 |
Disclosed is a BCR-ABL kinase inhibitor. The BCR-ABL kinase inhibitor comprises a compound of formula I or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof, wherein R1, R2, R3, R4, R5 an...
|
|
WO/2016/168420A1 |
Described herein are methods using compounds of Formula (I), (Ia), and (Ib) to treat or prevent a lysosomal storage disorder, methods of making such compounds, and methods of using pharmaceutical compositions and medicaments containing s...
|
|
WO/2016/168444A1 |
The present disclosure generally relates to methods of treating hemolytic diseases such as sickle cell anemia using kinase inhibitors, for example, compounds that inhibit the spleen tyrosine kinse (SYK). In some embodiments a method is p...
|
|
WO/2016/163531A1 |
The present invention makes it possible to avoid Ullmann condensation, which decreases in yield in association with an increase in production scale, unlike known production processes by changing a starting substance, and to safely and st...
|
|
WO/2016/164217A1 |
The present invention relates to combination treatment methods for treating cancer, particularly non-small cell lung cancer (NSCLC). More specifically, the invention relates to methods of treating or managing cancer, particularly NSCLC, ...
|
|
WO/2016/164675A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, ...
|
|
WO/2016/161286A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2016/159836A1 |
The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimid
ine-4-ol derivatives, havin...
|
|
WO/2016/156240A1 |
The present invention relates to an improved process for preparing Idelalisib (1). In this process, acid addition salts of idelalisamine (2) are useful intermediates for purification purposes.
|
|
WO/2016/161269A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2016/159049A1 |
The present invention pertains to a compound that can be useful as an agent for the treatment and/or prevention of cancer, hepatitis, liver fibrosis, fatty liver, and the like.
|
|
WO/2016/149765A1 |
The present disclosure relates generally to compounds having activity as voltage-gated sodium channel blockers and their use in the field of therapeutic treatment, including the therapy or management of conditions associated with excessi...
|
|
WO/2016/151104A1 |
The present invention relates to a process comprising reacting p-fluorobenzaldehyde, 4-methyl-3-oxopentanenitrile and urea in a first reaction mixture comprising a first organic solvent, thereby obtaining an intermediate mixture comprisi...
|
|
WO/2016/150255A1 |
Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, wh...
|
|
WO/2016/151085A1 |
The present invention relates to a compound or a pharmaceutically acceptable salt thereof or a solvate thereof or a pharmaceutical composition comprising said compound, a process for obtaining or screening for a toll-like receptor 9 (TLR...
|
|
WO/2016/147053A1 |
The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, suc...
|
|
WO/2016/145478A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of kidney and/or liver disease.
|
|
WO/2016/146074A1 |
A compound represented by formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of ...
|
|
WO/2016/146607A1 |
The invention relates to a novel and improved method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo
-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I), and to the produc...
|
|
WO/2016/145614A1 |
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present inven...
|
|
WO/2015/146870A9 |
Provided are a pyrimidine compound represented by formula (1) having excellent harmful pest-exterminating potency, a harmful pest-exterminating agent comprising the compound and an inert carrier, and a method for exterminating harmful pe...
|
|
WO/2016/138648A1 |
The present disclosure relates to a method of synthesizing 5-chloro-N2- (2-isopropoxy-5-methyl-4- (piperidin-4-yl) phenyl) -N4- [2- (propane-2-sulfonyl) -phenyl] -pyrimidine-2, 4-diamine (ceritinib) and/or intermediates thereof, their us...
|
|
WO/2016/139677A1 |
The present invention relates to an improved process for the preparation of 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-di
hydropyrimidin-1(2H)-yl} methyl)benzonitrile represented by the following structural formula-1 and p...
|
|
WO/2016/141220A1 |
Various embodiments described herein are directed to compounds of formula (I), (II), (III) or (IV) for use as potent inhibitors of HIV integrase and for treatment of patients afflicted with AIDS. A major challenge of human immunodeficien...
|
|
WO/2016/134056A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/133832A1 |
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including m...
|
|
WO/2016/134054A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/134057A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/131810A1 |
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *Δ**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attac...
|
|
WO/2016/010662A9 |
A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein...
|
|
WO/2016/134051A1 |
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...
|
|
WO/2016/133342A1 |
The present specification relates to a double-spiro type compound and an organic light-emitting device containing the same.
|
|
WO/2016/127873A1 |
The present invention provides an isothiocyanate compound and an application thereof. The compound is an aryl substituted isothiocyanate compound that has a structure in the general formula I. The isothiocyanate compound in the present i...
|
|
WO/2016/128140A1 |
Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
|
|
WO/2016/129490A1 |
Provided is a polar compound having high chemical stability, high ability to align liquid crystal molecules, and high solubility in a liquid crystal composition, and which has a large voltage holding ratio when used in a liquid crystal d...
|
|
WO/2016/129983A1 |
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections.
|
|
WO/2016/127949A1 |
Disclosed is a pyrimidine derivative for use as a kinase inhibitor. The pyrimidine derivative of the present invention may be used as a kinase inhibitor and is used to treat because drug-resistant tumors caused by T790M mutation.
|
|
WO/2016/127213A1 |
The invention relates to novel heterocyclic compounds of Formula (I) which inhibit necroptosis and methods for their use. The compounds may be useful in the treatment of conditions associated with deregulated necroptosis.
|
|
WO/2016/126707A1 |
The present invention relates to methods for treating Charcot-Marie-Tooth Disease (CMT) with apilimod and related compositions and methods.
|
|
WO/2016/123717A1 |
A method of preventing or reducing the level of degradation of an organic substrate is described, wherein a composition is formed that includes the organic substrate together with an effective amount of a sacrificial base and a diarylami...
|
|
WO/2016/123706A1 |
A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders.
|
|
WO/2016/126926A1 |
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections...
|
|
WO/2016/126085A2 |
The present invention relates to a novel heterocyclic compound capable of suppressing activity of cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an active ingredient. The heterocyclic compound accor...
|
|
WO/2016/126570A1 |
The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.
|
|
WO/2016/123291A1 |
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provid...
|
|
WO/2016/120355A2 |
The present invention relates to the use of phenylpyrimidines of formula (I) or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, specific phenylpyrimidine...
|
|
WO/2016/119349A1 |
Disclosed is a preparation method for a compound represented by formula (I). The compound represented by formula (I) is prepared by reacting a compound represented by formula (II) with a compound represented by formula (III) under the ca...
|
|
WO/2016/119017A1 |
The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).
|
